Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation

Areej El-Jawahri, Yi Bin Chen, Ruta Brazauskas, Naya He, Stephanie J. Lee, Jennifer M. Knight, Navneet Majhail, David Buchbinder, Raquel M. Schears, Baldeep M. Wirk, William A. Wood, Ibrahim Ahmed, Mahmoud Aljurf, Jeff Szer, Sara M. Beattie, Minoo Battiwalla, Christopher Dandoy, Miguel Angel Diaz, Anita D'Souza, Cesar O. FreytesJames Gajewski, Usama Gergis, Shahrukh K. Hashmi, Ann Jakubowski, Rammurti T. Kamble, Tamila Kindwall-Keller, Hilard M. Lazarus, Adriana K. Malone, David I. Marks, Kenneth Meehan, Bipin N. Savani, Richard F. Olsson, David Rizzieri, Amir Steinberg, Dawn Speckhart, David Szwajcer, Helene Schoemans, Sachiko Seo, Celalettin Ustun, Yoshiko Atsuta, Jignesh Dalal, Carmem Sales-Bonfim, Nandita Khera, Theresa Hahn, Wael Saber

Research output: Contribution to journalArticlepeer-review

53 Scopus citations


BACKGROUND: To evaluate the impact of depression before autologous and allogeneic hematopoietic cell transplantation (HCT) on clinical outcomes post-transplantation. METHODS: We analyzed data from the Center for International Blood and Marrow Transplant Research to compare outcomes after autologous (n = 3786) or allogeneic (n = 7433) HCT for adult patients with hematologic malignancies with an existing diagnosis of pre-HCT depression requiring treatment versus those without pre-HCT depression. Using Cox regression models, we compared overall survival (OS) between patients with or without depression. We compared the number of days alive and out of the hospital in the first 100 days post-HCT using Poisson models. We also compared the incidence of grade 2-4 acute and chronic graft-versus-host disease (GVHD) in allogeneic HCT. RESULTS: The study included 1116 (15%) patients with pre-transplant depression and 6317 (85%) without depression who underwent allogeneic HCT between 2008 and 2012. Pre-transplant depression was associated with lower OS (hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.04-1.23; P = 0.004) and a higher incidence of grade 2-4 acute GVHD (HR, 1.25; 95% CI, 1.14-1.37; P < 0.0001), but similar incidence of chronic GVHD. Pre-transplant depression was associated with fewer days-alive-and-out-of-the hospital (means ratio [MR] = 0.97; 95% CI, 0.95-0.99; P = 0.004). There were 512 (13.5%) patients with Pre-transplant depression and 3274 (86.5%) without depression who underwent autologous HCT. Pre-transplant depression in autologous HCT was not associated with OS (HR, 1.15; 95% CI, 0.98-1.34; P = 0.096) but was associated with fewer days alive and out of the hospital (MR, 0.98; 95% CI, 0.97-0.99; P = 0.002). CONCLUSION: Pre-transplant depression was associated with lower OS and higher risk of acute GVHD among allogeneic HCT recipients and fewer days alive and out of the hospital during the first 100 days after autologous and allogeneic HCT. Patients with pre-transplant depression represent a population that is at risk for post-transplant complications. Cancer 2017;123:1828–1838.

Original languageEnglish (US)
Pages (from-to)1828-1838
Number of pages11
Issue number10
StatePublished - May 15 2017

Bibliographical note

Funding Information:
The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases; a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from Alexion; Amgen, Inc.*; Anonymous donation to the Medical College of Wisconsin; Be the Match Foundation; Bristol Myers Squibb Oncology*; Celgene Corporation*; Chimerix, Inc.*; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.*; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jazz Pharmaceuticals, Inc.*; Jeff Gordon Children's Foundation; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Mesoblast; Millennium: The Takeda Oncology Co.*; Miltenyi Biotec, Inc.*; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co, Ltd. (Japan); Oxford Immunotec; Perkin Elmer, Inc.; Pharmacyclics; Sanofi US*; Seattle Genetics; Sigma-Tau Pharmaceuticals; Spectrum Pharmaceuticals, Inc.*; St. Baldrick's Foundation; Sunesis Pharmaceuticals, Inc.*; Swedish Orphan Biovitrum, Inc.; Telomere Diagnostics, Inc.; TerumoBCT; Therakos, Inc.; University of Minnesota; and Wellpoint, Inc.* The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US government.

Publisher Copyright:
© 2016 American Cancer Society


  • GVHD
  • autologous HCT
  • depression
  • pre-HCT depression
  • transplant outcomes


Dive into the research topics of 'Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this